The EC's decision was based on results from a Phase III trial of Blincyto with multiphase consolidation chemotherapy.

The European Commission (EC) has approved Blincyto (blinatumomab) monotherapy as part of consolidation therapy for the treatment of adults with newly-diagnosed Philadelphia chromosome-negative ...

Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.

Amgen Inc . (NASDAQ:AMGN), a leading biotechnology company with a market capitalization of $151.3 billion, is navigating a ...

On January 23, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a ...

BioAge scrapped the drug at the center of its $198 million initial public offering last year. Elsewhere, Akero and 89bio raised $600 million combined and Allakos laid off staff.

Amgen Inc (AMGN) stock saw a decline, ending the day at $280.3 which represents a decrease of $-2.65 or -0.94% from the prior close of $282.95. The stock opened at $280.13 and touched a low of $279.97 ...

Many Americans support prohibiting commercials for prescription drugs on television. But enacting that ban could be ...

Treatment with romosozumab led to improvements in bone microarchitecture among postmenopausal women with osteoporosis.

As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...

Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

The soaring demand for antidiabetic and weight-loss drugs has lured in many biotech and big Pharma companies. Onto this ...